Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 381-391

  Peyruchaud, Olivier ^a  

^a INSERM   (France)

Author keywords

Antagonists; Autotaxin; Cancer cells; Lysophosphatidic acid; Receptors; Sphingosine 1 phosphate; Spkingosine kinase

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ANTINEOPLASTIC AGENT; CYCLOSPORIN; FINGOLIMOD; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID ANTAGONIST; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHOLIPID; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; SPHINGOSINE PHOSPHATE 1 ANTIBODY; SPHINGOSINE PHOSPHATE 1 INHIBITOR; UNCLASSIFIED DRUG; VPC 25239; DRUG DERIVATIVE; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CLINICAL TRIAL; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; HUMAN; LIPOGENESIS; LIVER CELL CARCINOMA; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR INTERACTION; NONHUMAN; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASMS; PROPYLENE GLYCOLS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 67649807699     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909040381     Document Type: Article

References (123)

1. Liu, H.; Chakravarty, D.; Maceyka, M.; Milstien, S.; Spiegel, S. Sphingosine kinases: a novel family of lipid kinases. Prog. Nucleic Acid. Res. Mol. Biol., 2002, 71, 493-511.
2. Tokumura, A.; Majima, E.; Kariya, Y.; Tominaga, K.; Kogure, K.; Yasuda, K.; Fukuzawa, K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem., 2002, 277(42), 39436-39442.
3. Clair, T.; Aoki, J.; Koh, E.; Bandle, R. W.; Nam, S. W.; Ptaszynska, M. M.; Mills, G. B.; Schiffmann, E.; Liotta, L. A.; Stracke, M. L. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res., 2003, 63(17), 5446-5453.
4. Eichholtz, T.; Jalink, K.; Fahrenfort, I.; Moolenaar, W. H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J., 1993, 291(3), 677-680.
5. Yatomi, Y.; Igarashi, Y.; Yang, L.; Hisano, N.; Qi, R.; Asazuma, N.; Satoh, K.; Ozaki, Y.; Kume, S. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J. Biochem. (Tokyo), 1997, 121(5), 969-973.
6. Lee, M. J.; Evans, M.; Hla, T. The inducible G protein-coupled receptor edg-1 signals via the G(i)/mitogen-activated protein kinase pathway. J. Biol. Chem., 1996, 271(19), 11272-11279.
7. Hecht, J. H.; Weiner, J. A.; Post, S. R.; Chun, J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell. Biol., 1996, 135(4), 1071-1083.
8. An, S.; Bleu, T.; Hallmark, O. G.; Goetzl, E. J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem., 1998, 273(14), 7906-7910.
9. Bandoh, K.; Aoki, J.; Hosono, H.; Kobayashi, S.; Kobayashi, T.; Murakami-Murofushi, K.; Tsujimoto, M.; Arai, H.; Inoue, K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem., 1999, 274(39), 27776-27785.
10. An, S.; Dickens, M. A.; Bleu, T.; Hallmark, O. G.; Goetzl, E. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. J. Biochem. Biophys. Res. Commun., 1997, 231(3), 619-622.
11. Lee, M. J.; Van Brocklyn, J. R.; Thangada, S.; Liu, C. H.; Hand, A. R.; Menzeleev, R.; Spiegel, S.; Hla, T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science, 1998, 279(5356), 1552-1555.
12. Im, D. S.; Heise, C. E.; Ancellin, N.; O'Dowd, B. F.; Shei, G. J.; Heavens, R. P.; Rigby, M. R.; Hla, T.; Mandala, S.; McAllister, G.; George, S. R.; Lynch, K. R. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J. Biol. Chem., 2000, 275(19), 14281-14286.
13. Van Brocklyn, J. R.; Graler, M. H.; Bernhardt, G.; Hobson, J. P.; Lipp, M.; Spiegel, S. Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood, 2000, 95(8), 2624-2629.
14. MacLennan, A. J.; Carney, P. R.; Zhu, W. J.; Chaves, A. H.; Garcia, J.; Grimes, J. R.; Anderson, K. J.; Roper, S. N.; Lee, N. An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur. J. Neurosci., 2001, 14(2), 203-209.
15. Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the edg family. J. Biol. Chem., 2003, 278(28), 25600-25606.
16. Kotarsky, K.; Boketoft, A.; Bristulf, J.; Nilsson, N. E.; Norberg, A.; Hansson, S.; Owman, C.; Sillard, R.; Leeb-Lundberg, L. M.; Olde, B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther., 2006, 318(2), 619-628.
17. Tabata, K.; Baba, K.; Shiraishi, A.; Ito, M.; Fujita, N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun., 2007, 363(3), 861-866.
18. Pasternack, S. M.; von Kugelgen, I.; Aboud, K. A.; Lee, Y. A.; Ruschendorf, F.; Voss, K.; Hillmer, A. M.; Molderings, G. J.; Franz, T.; Ramirez, A.; Nurnberg, P.; Nothen, M. M.; Betz, R. C. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet., 2008, 40(3), 329-334.
19. Liu, Y.; Wada, R.; Yamashita, T.; Mi, Y.; Deng, C. X.; Hobson, J. P.; Rosenfeldt, H. M.; Nava, V. E.; Chae, S. S.; Lee, M. J.; Liu, C. H.; Hla, T.; Spiegel, S.; Proia, R. L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest., 2000, 106(8), 951-961.
20. Contos, J. J. A.; Fukushima, N.; Weiner, J. A.; Kaushal, D.; Chun, J. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. Proc. Natl. Acad. Sci. USA, 2000, 97(24), 13384-13389.
21. Ye, X.; Hama, K.; Contos, J. J.; Anliker, B.; Inoue, A.; Skinner, M. K.; Suzuki, H.; Amano, T.; Kennedy, G.; Arai, H.; Aoki, J.; Chun, J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature, 2005, 435(7038), 104-108.
22. Shimomura, Y.; Wajid, M.; Ishii, Y.; Shapiro, L.; Petukhova, L.; Gordon, D.; Christiano, A. M. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nat. Genet., 2008, 40(3), 335-339.
23. Goetzl, E. J.; An, S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J., 1998, 12(15), 1589-1598.
24. Nava, V. E.; Cuvillier, O.; Edsall, L. C.; Kimura, K.; Milstien, S.; Gelmann, E. P.; Spiegel, S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res., 2000, 60(16), 4468-4474.
25. Pchejetski, D.; Golzio, M.; Bonhoure, E.; Calvet, C.; Doumerc, N.; Garcia, V.; Mazerolles, C.; Rischmann, P.; Teissie, J.; Malavaud, B.; Cuvillier, O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res., 2005, 65(24), 1166711675.
26. French, K. J.; Schrecengost, R. S.; Lee, B. D.; Zhuang, Y.; Smith, S. N.; Eberly, J. L.; Yun, J. K.; Smith, C. D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63(18), 5962-5969.
27. Nava, V. E.; Hobson, J. P.; Murthy, S.; Milstien, S.; Spiegel, S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell. Res., 2002, 281(1), 115-127.
28. Chae, S.-S.; Paik, J.-H.; Furneaux, H.; Hla, T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest., 2004, 114(8), 1082-1089.
29. Lee, T. K.; Man, K.; Ho, J. W.; Sun, C. K.; Ng, K. T.; Wang, X. H.; Wong, Y. C.; Ng, I. O.; Xu, R.; Fan, S. T. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis, 2004, 25(12), 2397-2405.
30. Shen, Y.; Cai, M.; Xia, W.; Liu, J.; Zhang, Q.; Xie, H.; Wang, C.; Wang, X.; Zheng, S. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett., 2007, 254(2), 288-297.
31. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol., 2003, 138, 1303-1312.
32. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol., 2003, 169(7), 2372-2377.
33. Sukocheva, O.; Wadham, C.; Holmes, A.; Albanese, N.; Verrier, E.; Feng, F.; Bernal, A.; Derian, C. K.; Ullrich, A.; Vadas, M. A.; Xia, P. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J. Cell. Biol., 2006, 173(2), 301-310.
34. French, K. J.; Upson, J. J.; Keller, S. N.; Zhuang, Y.; Yun, J. K.; Smith, C. D. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther., 2006, 318(2), 596-603.
35. Visentin, B.; Vekich, J. A.; Sibbald, B. J.; Cavalli, A. L.; Moreno, K. M.; Matteo, R. G.; Garland, W. A.; Lu, Y.; Yu, S.; Hall, H. S.; Kundra, V.; Mills, G. B.; Sabbadini, R. A. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell., 2006, 9(3), 225-238.
36. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004, 427(6972), 355-360.
37. Wang, J. D.; Takahara, S.; Nonomura, N.; Ichimaru, N.; Toki, K.; Azuma, H.; Matsumiya, K.; Okuyama, A.; Suzuki, S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate, 1999, 40(1), 50-55.
38. Hung, J. H.; Lu, Y. S.; Wang, Y. C.; Ma, Y. H.; Wang, D. S.; Kulp, S. K.; Muthusamy, N.; Byrd, J. C.; Cheng, A. L.; Chen, C. S. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res., 2008, 68(4), 1204-1212.
39. Ubai, T.; Azuma, H.; Kotake, Y.; Inamoto, T.; Takahara, K.; Ito, Y.; Kiyama, S.; Sakamoto, T.; Horie, S.; Muto, S.; Takahara, S.; Otsuki, Y.; Katsuoka, Y. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anti-cancer Res., 2007, 27(1), 75-88.
40. Yasui, H.; Hideshima, T.; Raje, N.; Roccaro, A. M.; Shiraishi, N.; Kumar, S.; Hamasaki, M.; Ishitsuka, K.; Tai, Y. T.; Podar, K.; Catley, L.; Mitsiades, C. S.; Richardson, P. G.; Albert, R.; Brinkmann, V.; Chauhan, D.; Anderson, K. C. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res., 2005, 65(16), 7478-7484.
41. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117(9), 2408-2421.
42. LaMontagne, K.; Littlewood-Evans, A.; Schnell, C.; O'Reilly, T.; Wyder, L.; Sanchez, T.; Probst, B.; Butler, J.; Wood, A.; Liau, G.; Billy, E.; Theuer, A.; Hla, T.; Wood, J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res., 2006, 66(1), 221-231.
43. Azuma, H.; Horie, S.; Muto, S.; Otsuki, Y.; Matsumoto, K.; Morimoto, J.; Gotoh, R.; Okuyama, A.; Suzuki, S.; Katsuoka, Y.; Takahara, S. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res., 2003, 23(4), 3183-3193.
44. Lepley, D.; Paik, J. H.; Hla, T.; Ferrer, F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res., 2005, 65(9), 3788-3795.
45. Schmid, G.; Guba, M.; Ischenko, I.; Papyan, A.; Joka, M.; Schrepfer, S.; Bruns, C. J.; Jauch, K. W.; Heeschen, C.; Graeb, C. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell. Biochem., 2007, 101(1), 259-270.
46. Permpongkosol, S.; Wang, J. D.; Takahara, S.; Matsumiya, K.; Nonomura, N.; Nishimura, K.; Tsujimura, A.; Kongkanand, A.; Okuyama, A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int. J. Cancer, 2002, 98(2), 167-172.
47. Sonoda, Y.; Yamamoto, D.; Sakurai, S.; Hasegawa, M.; Aizu-Yokota, E.; Momoi, T.; Kasahara, T. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun., 2001, 281(2), 282-288.
48. Liu, Q.; Zhao, X.; Frissora, F.; Ma, Y.; Santhanam, R.; Jarjoura, D.; Lehman, A.; Perrotti, D.; Chen, C. S.; Dalton, J. T.; Muthusamy, N.; Byrd, J. C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/ lymphoma. Blood, 2008, 111(1), 275-284.
49. Oo, M. L.; Thangada, S.; Wu, M. T.; Liu, C. H.; Macdonald, T. L.; Lynch, K. R.; Lin, C. Y.; Hla, T. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem., 2007, 282(12), 9082-9089.
50. Zhou, C.; Ling, M. T.; Kin-Wah Lee, T.; Man, K.; Wang, X.; Wong, Y. C. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett., 2006, 233(1), 36-47.
51. Lee, T. K.; Man, K.; Ho, J. W.; Wang, X. H.; Poon, R. T.; Sun, C. K.; Ng, K. T.; Ng, I. O.; Xu, R.; Fan, S. T. Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis, 2005, 26(3), 681-687.
52. Lee, T. K.; Man, K.; Ho, J. W.; Wang, X. H.; Poon, R. T.; Xu, Y.; Ng, K. T.; Chu, A. C.; Sun, C. K.; Ng, I. O.; Sun, H. C.; Tang, Z. Y.; Xu, R.; Fan, S. T. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res., 2005, 11(23), 8458-8466.
53. Ng, K. T.; Man, K.; Ho, J. W.; Sun, C. K.; Lee, T. K.; Zhao, Y.; Lo, C. M.; Poon, R. T.; Fan, S. T. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. Int. J. Oncol., 2007, 30(2), 375-380.
54. Chua, C. W.; Lee, D. T.; Ling, M. T.; Zhou, C.; Man, K.; Ho, J.; Chan, F. L.; Wang, X.; Wong, Y. C. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer, 2005, 117(6), 1039-1048.
55. Ho, J. W.; Man, K.; Sun, C. K.; Lee, T. K.; Poon, R. T.; Fan, S. T. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther., 2005, 4(9), 1430-1438.
56. Schmid, G.; Guba, M.; Papyan, A.; Ischenko, I.; Bruckel, M.; Bruns, C. J.; Jauch, K. W.; Graeb, C. FTY720 inhibits tumor growth and angiogenesis. Transplant. Proc., 2005, 37(1), 110-111.
57. Azuma, H.; Takahara, S.; Ichimaru, N.; Wang, J. D.; Itoh, Y.; Otsuki, Y.; Morimoto, J.; Fukui, R.; Hoshiga, M.; Ishihara, T.; Nonomura, N.; Suzuki, S.; Okuyama, A.; Katsuoka, Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res., 2002, 62(5), 1410-1419.
58. van Meeteren, L. A.; Brinkmann, V.; Saulnier-Blache, J. S.; Lynch, K. R.; Moolenaar, W. H. Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. Cancer Lett., 2008, 266(2), 203-208.
59. van Meeteren, L. A.; Ruurs, P.; Stortelers, C.; Bouwman, P.; van Rooijen, M. A.; Pradere, J. P.; Pettit, T. R.; Wakelam, M. J.; Saulnier-Blache, J. S.; Mummery, C. L.; Moolenaar, W. H.; Jonkers, J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol., 2006, 26(13), 5015-5022.
60. Tanaka, M.; Okudaira, S.; Kishi, Y.; Ohkawa, R.; Iseki, S.; Ota, M.; Noji, S.; Yatomi, Y.; Aoki, J.; Arai, H. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem., 2006, 281(35), 25822-25830.
61. Mills, G. B.; Moolenaar, W. H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer, 2003, 3(8), 582-591.
62. Boucharaba, A.; Serre, C.-M.; Gres, S.; Saulnier-Blache, J. S.; Bordet, J.-C.; Guglielmi, J.; Clezardin, P.; Peyruchaud, O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest., 2004, 114(12), 1714-1725.
63. Osada, M.; Yatomi, Y.; Ohmori, T.; Ikeda, H.; Ozaki, Y. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem. Biophys. Res. Commun., 2002, 299(3), 483-487.
64. Arikawa, K.; Takuwa, N.; Yamaguchi, H.; Sugimoto, N.; Kitayama, J.; Nagawa, H.; Takehara, K.; Takuwa, Y. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem., 2003, 278(35), 32841-32851.
65. Davis, M.D.; Clemens, J.J.; Macdonald, T.L.; Lynch, K.R. Sphingosine 1-Phosphate Analogs as Receptor Antagonists. J. Biol. Chem., 2005, 280(11), 9833-9841.
66. Inoki, I.; Takuwa, N.; Sugimoto, N.; Yoshioka, K.; Takata, S.; Kaneko, S.; Takuwa, Y. Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor. Biochem. Biophys. Res. Commun., 2006, 346(1), 293-300.
67. Jo, E.; Sanna, M. G.; Gonzalez-Cabrera, P. J.; Thangada, S.; Tigyi, G.; Osborne, D. A.; Hla, T.; Parrill, A. L.; Rosen, H. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol., 2005, 12(6), 703-715.
68. Koide, Y.; Uemoto, K.; Hasegawa, T.; Sada, T.; Murakami, A.; Takasugi, H.; Sakurai, A.; Mochizuki, N.; Takahashi, A.; Nishida, A. Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. J. Med. Chem., 2007, 50(3), 442-454.
69. Xu, Y.; Shen, Z.; Wiper, D. W.; Wu, M.; Morton, R. E.; Elson, P.; Kennedy, A. W.; Belinson, J.; Markman, M.; Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, 1998, 280(8), 719-723.
70. Shen, Z.; Belinson, J.; Morton, R. E.; Xu, Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol. Oncol., 1998, 71(3), 364-368.
71. Fang, X.; Schummer, M.; Mao, M.; Yu, S.; Tabassam, F. H.; Swaby, R.; Hasegawa, Y.; Tanyi, J. L.; LaPushin, R.; Eder, A.; Jaffe, R.; Erickson, J.; Mills, G. B. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta., 2002, 1582(1-3), 257-264.
72. Xie, Y.; Gibbs, T. C.; Mukhin, Y. V.; Meier, K. E. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J. Biol. Chem., 2002, 277(36), 32516-32526.
73. Stracke, M. L.; Krutzsch, H. C.; Unsworth, E. J.; Arestad, A.; Cioce, V.; Schiffmann, E.; Liotta, L. A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem., 1992, 267(4), 2524-2529.
74. Umezu-Goto, M.; Kishi, Y.; Taira, A.; Hama, K.; Dohmae, N.; Takio, K.; Yamori, T.; Mills, G. B.; Inoue, K.; Aoki, J.; Arai, H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell. Biol., 2002, 158(2), 227-233.
75. Koh, E.; Clair, T.; Woodhouse, E. C.; Schiffmann, E.; Liotta, L.; Stracke, M. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer Res., 2003, 63(9), 2042-2045.
76. Yang, S. Y.; Lee, J.; Park, C. G.; Kim, S.; Hong, S.; Chung, H. C.; Min, S. K.; Han, J. W.; Lee, H. W.; Lee, H. Y. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis, 2002, 19(7), 603-608.
77. Umezu-Goto, M.; Tanyi, J.; Lahad, J.; Liu, S.; Yu, S.; Lapushin, R.; Hasegawa, Y.; Lu, Y.; Trost, R.; Bevers, T.; Jonasch, E.; Aldape, K.; Liu, J.; James, R. D.; Ferguson, C. G.; Xu, Y.; Prestwich, G. D.; Mills, G. B. Lysophosphatidic acid production and action: Validated targets in cancer? J. Cell Biochem., 2004, 92(6), 1115-1140
78. Kehlen, A.; Englert, N.; Seifert, A.; Klonisch, T.; Dralle, H.; Langner, J.; Hoang-Vu, C. Expression, regulation and function of autotaxin in thyroid carcinomas. Int. J. Cancer, 2004, 109(6), 833-838.
79. Yang, Y.; Mou, L.; Liu, N.; Tsao, M. S. Autotaxin expression in non-small-cell lung cancer. Am. J. Respir. Cell. Mol. Biol., 1999, 21(2), 216-222.
80. Kawagoe, H.; Stracke, M. L.; Nakamura, H.; Sano, K. Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Res., 1997, 57(12), 2516-2521.
81. Zhang, G.; Zhao, Z.; Xu, S.; Ni, L.; Wang, X. Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin. Med. J. (Engl), 1999, 112(4), 330-332.
82. Shida, D.; Watanabe, T.; Aoki, J.; Hama, K.; Kitayama, J.; Sonoda, H.; Kishi, Y.; Yamaguchi, H.; Sasaki, S.; Sako, A.; Konishi, T.; Arai, H.; Nagawa, H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab. Invest., 2004, 84(10), 1352-1362.
83. Schulte, K. M.; Beyer, A.; Kohrer, K.; Oberhauser, S.; Roher, H. D. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int. J. Cancer, 2001, 92(2), 249-256.
84. Kitayama, J.; Shida, D.; Sako, A.; Ishikawa, M.; Hama, K.; Aoki, J.; Arai, H.; Nagawa, H. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res., 2004, 6(6), R640-646.
85. Miele, M. E.; De La Rosa, A.; Lee, J. H.; Hicks, D. J.; Dennis, J. U.; Steeg, P. S.; Welch, D. R. Suppression of human melanoma metastasis following introduction of chromosome 6 is independent of NME1 (Nm23). Clin. Exp. Metastasis, 1997, 15(3), 259-265.
86. Leone, A.; Flatow, U.; VanHoutte, K.; Steeg, P. S. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene, 1993, 8(9), 2325-2333.
87. Lim, S.; Lee, H. Y.; Lee, H. Inhibition of colonization and cell-matrix adhesion after nm23-H1 transfection of human prostate carcinoma cells. Cancer Lett., 1998, 133(2), 143-149.
88. Suzuki, E.; Ota, T.; Tsukuda, K.; Okita, A.; Matsuoka, K.; Murakami, M.; Doihara, H.; Shimizu, N. nm23-H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation. Int. J. Cancer, 2004, 108(2), 207-211.
89. Horak, C. E.; Lee, J. H.; Elkahloun, A. G.; Boissan, M.; Dumont, S.; Maga, T. K.; Arnaud-Dabernat, S.; Palmieri, D.; Stetler-Stevenson, W. G.; Lacombe, M. L.; Meltzer, P. S.; Steeg, P. S. Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res., 2007, 67(15), 7238.
90. Horak, C. E.; Mendoza, A.; Vega-Valle, E.; Albaugh, M.; Graff-Cherry, C.; McDermott, W. G.; Hua, E.; Merino, M. J.; Steinberg, S. M.; Khanna, C.; Steeg, P. S. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res., 2007, 67(24), 11751-11759.
91. Moolenaar, W. H. Development of our current understanding of bioactive lysophospholipids. Ann. N. Y. Acad. Sci., 2000, 905, 1-10.
92. Moolenaar, W. H.; van Meeteren, L. A.; Giepmans, B. N. The ins and outs of lysophosphatidic acid signaling. Bioessays, 2004, 26(8), 870-881.
93. Yang, M.; Zhong, W. W.; Srivastava, N.; Slavin, A.; Yang, J.; Hoey, T.; An, S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. USA, 2005, 102(17), 6027-6032.
94. Zhang, H.; Bialkowska, A.; Rusovici, R.; Chanchevalap, S.; Shim, H.; Katz, J. P.; Yang, V. W.; Yun, C. C. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J. Biol. Chem., 2007, 282(21), 15541-15549.
95. Shida, D.; Kitayama, J.; Yamaguchi, H.; Okaji, Y.; Tsuno, N. H.; Watanabe, T.; Takuwa, Y.; Nagawa, H. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res., 2003, 63(7), 1706-1711.
96. Hama, K.; Aoki, J.; Fukaya, M.; Kishi, Y.; Sakai, T.; Suzuki, R.; Ohta, H.; Yamori, T.; Watanabe, M.; Chun, J.; Arai, H. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J. Biol. Chem., 2004, 279(17), 17634-17639.
97. Daaka, Y. Mitogenic action of LPA in prostate. Biochim. Biophys. Acta, 2002, 1582(1-3), 265-269.
98. Guo, R.; Kasbohm, E. A.; Arora, P.; Sample, C. J.; Baban, B.; Sud, N.; Sivashanmugam, P.; Moniri, N. H.; Daaka, Y. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer Cells. Endocrinology, 2006, 147(10), 4883-4892.
99. Goetzl, E. J.; Dolezalova, H.; Kong, Y.; Zeng, L. Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res., 1999, 59(18), 4732-4737.
100. Boucharaba, A.; Serre, C. M.; Guglielmi, J.; Bordet, J. C.; Clezardin, P.; Peyruchaud, O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA, 2006, 103(25), 9643-9648.
101. Guo, C.; Luttrell, L. M.; Price, D. T. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J. Urol., 2000, 163(3), 1027-1032.
102. Wang, L.; Cummings, R.; Zhao, Y.; Kazlauskas, A.; Sham, J. K. S.; Morris, A.; Georas, S.; Brindley, D. N.; Natarajan, V. Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-{beta} in human bronchial epithelial cells. J. Biol. Chem., 2003, 278(41), 39931-39940.
103. So, J.; Wang, F. Q.; Navari, J.; Schreher, J.; Fishman, D. A. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol. Oncol., 2005, 97(3), 870-878.
104. Fang, X.; Yu, S.; Bast, R. C.; Liu, S.; Xu, H. J.; Hu, S. X.; LaPushin, R.; Claret, F. X.; Aggarwal, B. B.; Lu, Y.; Mills, G. B. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem., 2004, 279(10), 9653-9661.
105. Chou, C. H.; Wei, L. H.; Kuo, M. L.; Huang, Y. J.; Lai, K. P.; Chen, C. A.; Hsieh, C. Y. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-{kappa}B pathway by lysophosphatidic acid, an ovarian cancer activating factor. Carcinogenesis, 2005, 26(1), 45-52.
106. Zhao, Y.; He, D.; Saatian, B.; Watkins, T.; Spannhake, E. W.; Pyne, N. J.; Natarajan, V. Regulation of Lysophosphatidic Acid-induced Epidermal Growth Factor Receptor Transactivation and Interleukin-8 Secretion in Human Bronchial Epithelial Cells by Protein Kinase C{delta}, Lyn Kinase, and Matrix Metalloproteinases. J. Biol. Chem., 2006, 281(28), 19501-19511.
107. Hu, Y. L.; Tee, M. K.; Goetzl, E. J.; Auersperg, N.; Mills, G. B.; Ferrara, N.; Jaffe, R. B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst., 2001, 93(10), 762-768.
108. Huang, M. C.; Lee, H. Y.; Yeh, C. C.; Kong, Y.; Zaloudek, C. J.; Goetzl, E. J. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene, 2004, 23(1), 122-129.
109. Lee, J.; Park, S. Y.; Lee, E. K.; Park, C. G.; Chung, H. C.; Rha, S. Y.; Kim, Y. K.; Bae, G. U.; Kim, B. K.; Han, J. W.; Lee, H. Y. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin. Cancer Res., 2006, 12(21), 6351-6358.
110. Virag, T.; Elrod, D. B.; Liliom, K.; Sardar, V. M.; Parrill, A. L.; Yokoyama, K.; Durgam, G.; Deng, W.; Miller, D. D.; Tigyi, G. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol. Pharmacol., 2003, 63(5), 1032-1042.
111. Heise, C. E.; Santos, W. L.; Schreihofer, A. M.; Heasley, B. H.; Mukhin, Y. V.; Macdonald, T. L.; Lynch, K. R. Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol. Pharmacol., 2001, 60(6), 1173-1180.
112. Fischer, D. J.; Nusser, N.; Virag, T.; Yokoyama, K.; Wang, D.; Baker, D. L.; Bautista, D.; Parrill, A. L.; Tigyi, G. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol., 2001, 60(4), 776-784.
113. Ohta, H.; Sato, K.; Murata, N.; Damirin, A.; Malchinkhuu, E.; Kon, J.; Kimura, T.; Tobo, M.; Yamazaki, Y.; Watanabe, T.; Yagi, M.; Sato, M.; Suzuki, R.; Murooka, H.; Sakai, T.; Nishitoba, T.; Im, D. S.; Nochi, H.; Tamoto, K.; Tomura, H.; Okajima, F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol., 2003, 64(4), 994-1005.
114. Bandoh, K.; Aoki, J.; Taira, A.; Tsujimoto, M.; Arai, H.; Inoue, K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett., 2000, 478(1-2), 159-165.
115. Hasegawa, Y.; Erickson, J. R.; Goddard, G. J.; Yu, S.; Liu, S.; Cheng, K. W.; Eder, A.; Bandoh, K.; Aoki, J.; Jarosz, R.; Schrier, A. D.; Lynch, K. R.; Mills, G. B.; Fang, X. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J. Biol. Chem., 2003, 278(14), 11962-11969.
116. Okusa, M. D.; Ye, H.; Huang, L.; Sigismund, L.; Macdonald, T.; Lynch, K. R. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal. Physiol., 2003, 285(3), F565-574.
117. van Meeteren, L. A.; Ruurs, P.; Christodoulou, E.; Goding, J. W.; Takakusa, H.; Kikuchi, K.; Perrakis, A.; Nagano, T.; Moolenaar, W. H. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J. Biol. Chem., 2005, 280(22), 21155-21161.
118. Cui, P.; McCalmont, W. F.; Tomsig, J. L.; Lynch, K. R.; Macdonald, T. L. alpha- and beta-Substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg. Med. Chem., 2008, 16(5), 2212-2225.
119. Cui, P.; Tomsig, J. L.; McCalmont, W. F.; Lee, S.; Becker, C. J.; Lynch, K. R.; Macdonald, T. L. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(6), 1634-1640.
120. Mukai, M.; Imamura, F.; Ayaki, M.; Shinkai, K.; Iwasaki, T.; Murakami-Murofushi, K.; Murofushi, H.; Kobayashi, S.; Yamamoto, T.; Nakamura, H.; Akedo, H. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). Int. J. Cancer, 1999, 81(6), 918-922.
121. Baker, D. L.; Fujiwara, Y.; Pigg, K. R.; Tsukahara, R.; Kobayashi, S.; Murofushi, H.; Uchiyama, A.; Murakami-Murofushi, K.; Koh, E.; Bandle, R. W.; Byun, H. S.; Bittman, R.; Fan, D.; Murph, M.; Mills, G. B.; Tigyi, G. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem., 2006, 281(32), 22786-22793.
122. Parrill, A. L.; Echols, U.; Nguyen, T.; Pham, T. C.; Hoeglund, A.; Baker, D. L. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg. Med. Chem., 2008, 16(4), 1784-1795.
123. Ferry, G.; Moulhara, NFerry, G.; Moulharat, N.; Pradere, J. P.; Desos, P.; Try, A.; Genton, A.; Giganti, A.; Bleucher-Gaudin, M.; Lonchampt, M.; Bertrand, M. and others. S32826: a nanomolar inhibitor of autotaxin. Discovery, synthesis and applications as a pharmacological tool. J. Pharmacol. Exp. Ther., 2008, 327(3), 80-819.